Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-16 · accession 0000875320-24-000068 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-21 | 2024-02-20 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $420.79 | -4,804 | 63.0K | -7% | -$2.02M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $422.54 | -7,872 | 67.8K | -10% | -$3.33M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | S | D | 4,804 | $420.79 | 63,042 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-16 | F | D | 4,499 | $424.01 | 71,219 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-20 | F | D | 3,373 | $420.58 | 67,846 | D | — | — |